Search results
Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration
Benzinga via Yahoo Finance· 3 weeks agoAfter topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co...
Merck could keep its patent edge by shifting Keytruda cancer drug to a simple shot
Reuters via Yahoo News· 1 year agoU.S. drugmaker Merck & Co hopes to patent a new formulation of its $20 billion cancer immunotherapy...
Merck Stock Has Been A Laggard For Seven Months. Is It Staging A Comeback?
Investor's Business Daily· 4 months agoMerck stock is shrugging off seven months of underperformance, shooting more than 7% higher in the...
Merck scraps third prostate cancer study as Keytruda therapy disappoints
Reuters via Yahoo News· 1 year agoMerck & Co on Tuesday scrapped a late-stage trial of a combination therapy with its cancer drug...
Moderna-Merck Partnered Cancer Vaccine Meets Primary Efficacy Endpoint, Stock Jumps
Benzinga via Yahoo Finance· 1 year agoModerna Inc (NASDAQ: MRNA) and Merck & Co Inc (NYSE: MRK) announced the Phase 2b...
Merck (MRK) Q3 Earnings Top Estimates, COVID Drug Boosts Sales
Zacks via Yahoo Finance· 7 months agoMerck MRK reported adjusted earnings of $2.13 per share for third-quarter 2023, beating the Zacks...
Patients with incurable cervical cancer to be offered new drug
Press Association News via AOL· 1 year agoPatients with incurable cervical cancer are to be offered a new treatment which could give them more...
Moderna (MRNA), Merck's Cancer Jab Delays Melanoma Recurrence
Zacks via Yahoo Finance· 1 year agoModerna MRNA and partner Merck MRK announced detailed results from the phase IIb KEYNOTE-942 study,...
Moderna, Merck cancer vaccine combo cut melanoma recurrence by 44% - study
Reuters via Yahoo Finance· 1 year agoAn experimental personalized melanoma vaccine developed by Moderna Inc given with Merck & Co's...
Merck profit tops Wall Street view on strong Keytruda sales
Reuters via Yahoo Finance· 2 years ago(Reuters) -Merck & Co on Thursday reported higher-than-expected second-quarter earnings and revenue...